| __timestamp | CRISPR Therapeutics AG | Viatris Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1513000 | 581800000 |
| Thursday, January 1, 2015 | 12573000 | 671900000 |
| Friday, January 1, 2016 | 42238000 | 876700000 |
| Sunday, January 1, 2017 | 69800000 | 857900000 |
| Monday, January 1, 2018 | 113773000 | 822200000 |
| Tuesday, January 1, 2019 | 179362000 | 778200000 |
| Wednesday, January 1, 2020 | 266946000 | 512600000 |
| Friday, January 1, 2021 | 438633000 | 681000000 |
| Saturday, January 1, 2022 | 461645000 | 662200000 |
| Sunday, January 1, 2023 | 387332000 | 910700000 |
Cracking the code
In the ever-evolving landscape of biotechnology and pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Viatris Inc. and CRISPR Therapeutics AG have demonstrated contrasting approaches to R&D investment.
From 2014 to 2023, Viatris Inc. consistently allocated a significant portion of its resources to R&D, with expenditures peaking in 2023 at approximately 910 million USD. This represents a 56% increase from its 2014 spending. In contrast, CRISPR Therapeutics AG, a pioneer in gene-editing technology, showed a remarkable growth trajectory, with R&D expenses surging by over 25,000% from 2014 to 2022, reaching a high of 462 million USD.
These figures underscore the dynamic nature of innovation strategies within the industry, highlighting how established firms and emerging biotech companies prioritize their R&D investments differently.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs CRISPR Therapeutics AG
R&D Insights: How Neurocrine Biosciences, Inc. and CRISPR Therapeutics AG Allocate Funds
Comparing Innovation Spending: Incyte Corporation and Viatris Inc.
Research and Development Investment: Viatris Inc. vs Corcept Therapeutics Incorporated
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and ACADIA Pharmaceuticals Inc.
Who Prioritizes Innovation? R&D Spending Compared for Viatris Inc. and Supernus Pharmaceuticals, Inc.
Viatris Inc. or Amphastar Pharmaceuticals, Inc.: Who Invests More in Innovation?
Viking Therapeutics, Inc. or CRISPR Therapeutics AG: Who Invests More in Innovation?
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Geron Corporation
Analyzing R&D Budgets: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc.